Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Allorion Raises $40 Million in A Round for Novel Oncology and Autoimmune Therapies

publication date: Nov 23, 2021

Allorion Therapeutics of Boston and Guangzhou completed a $40M Series A financing to develop next-gen precision medicines for oncology and autoimmune disease. Allorion claims its discovery platform combines technological breakthroughs in protein  structure, big data, machine learning and gene editing. The platform delivers highly selective small molecules, including covalent and allosteric inhibitors of well-validated  targets. Allorion is completing IND-enabling studies and IND applications for two drug candidates in China and the US. The A round was led by Qiming Venture Partners. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China